Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for Alzheimer’s disease, specifically targeti...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2025-03-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/58362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for Alzheimer’s disease, specifically targeting amyloid-β plaques, a hallmark of the disease. This review examines the pathogenesis of Alzheimer’s disease, the mechanism of action of these anti-amyloid therapies, and their potential benefits and associated risks, particularly amyloid-related imaging abnormalities (ARIA). While these therapies have demonstrated statistically significant efficacy in reducing amyloid plaques and decelerating cognitive decline, further research is required to confirm their long-term clinical benefits and establish a precise safety profile. Nonetheless, the approval of these monoclonal antibodies constitutes a significant advancement and potentially heralds the beginning of a new era in the treatment of Alzheimer’s disease.
|
|---|---|
| ISSN: | 2391-8306 |